ArticleCancers2013
Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?
Article in Cancers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Biological Evaluations and Computer-Aided Approaches of Janus Kinases 2 and 3 Inhibitors for Cancer Treatment: A Review.Pharmaceutics · 2024Review
- Nitazoxanide mitigates methotrexate hepatotoxicity in rats: role in inhibiting apoptosis and regulating endoplasmic reticulum stress.Frontiers in pharmacology · 2024Article
- Ultrastructural changes and IgA modulatory effect of commercial prebiotic and probiotic in murine giardiasis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer.BMC medicine · 2023Article
- Electrochemical DNA biosensors developed for the monitoring of biointeractions with drugs: a review.Turkish journal of chemistry · 2023Article
- Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells.Oncology letters · 2022Article
- NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.Expert review of anti-infective therapy · 2022Article
- Antitumor Activity of Nitazoxanide against Colon Cancers: Molecular Docking and Experimental Studies Based on Wnt/β-Catenin Signaling Inhibition.International journal of molecular sciences · 2021Article
- Synthesis, in vitro bioassays, and computational study of heteroaryl nitazoxanide analogs.Pharmacology research & perspectives · 2021Article
- Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-guérin association.World journal of urology · 2021Article
- A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19.European journal of pharmacology · 2021Review
- Targeting intracellular Leishmania (L.) infantum with nitazoxanide entrapped into phosphatidylserine-nanoliposomes: An experimental study.Chemico-biological interactions · 2020Article
- Article
- Chemoprophylactic activity of nitazoxanide in experimental model of mammary gland carcinoma in rats.3 Biotech · 2020Article
- Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.Molecular and cellular biochemistry · 2020Article
- Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma.Scientific reports · 2020Article
- Amixicile Reduces Severity of Cryptosporidiosis but Does Not HaveAntimicrobial agents and chemotherapy · 2018Article
- Protein disulfide isomerases as potential therapeutic targets for influenza A and B viruses.Virus research · 2018Article
- Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer.Oncotarget · 2017Article
- Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among gynecological malignancies epithelial ovarian cancer (EOC) is the leading cause of death. Despite improvements in conventional chemotherapy combinations, the overall cure rate has remained mostly stable over the years, and only 10%-15% of patients maintain a complete response following first-line therapy. To improve the efficacy of ovarian cancer chemotherapy it is essential to develop drugs with new mechanisms of action. Compared to normal tissues, protein disulfide isomerase (PDI) is overexpressed in ovarian tumors. PDI is a cellular enzyme in the lumen of the endoplasmic reticulum (ER) of eukaryotes or the periplasmic region of prokaryotes. This protein catalyzes the formation and breakage of disulphide bonds between cysteine residues in proteins, which affects protein folding. Selective inhibition of PDI activity has been exhibited both in vitro and in vivo anticancer activity in human ovarian cancer models. PDI inhibition caused accumulation of unfolded or misfolded proteins, which led to ER stress and the unfolded protein response (UPR), and in turn resulted in cell death. Nitazoxanide [NTZ: 2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide] is a thiazolide antiparasitic agent with excellent activity against a wide variety of protozoa and helminths. In this article, we propose that NTZ, acting as PDI inhibitor, may be a new and potent addition to the chemotherapeutic strategy against ovarian cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.